ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO350

Higher Type VI Collagen Formation Is Independently Associated with Increased Risk of Cardiovascular Events and Mortality in the Canagliflozin Cardiovascular Assessment Study (CANVAS)

Session Information

Category: Hypertension and CVD

  • 1403 Hypertension and CVD: Mechanisms

Authors

  • Rasmussen, Daniel Guldager Kring, Nordic Bioscience, Herlev, Denmark
  • Jatkoe, Timothy, Janssen Research & Development, LLC., Raritan, New Jersey, United States
  • Sparding, Nadja, Nordic Bioscience, Herlev, Denmark
  • Blair, Joseph Pm, Nordic Bioscience, Herlev, Denmark
  • Karsdal, Morten Asser, Nordic Bioscience, Herlev, Denmark
  • Gutstein, David E., Janssen Research & Development, LLC., Spring House, Pennsylvania, United States
  • Genovese, Federica, Nordic Bioscience, Herlev, Denmark
  • Hansen, Michael K., Janssen Research & Development, LLC., Spring House, Pennsylvania, United States
Background

Patients with type 2 diabetes are at significantly higher risk of experiencing cardiovascular complications. It has been shown that type VI collagen (COL VI) is markedly upregulated during pathogenic processes of the heart and vasculature. The role of COL VI biomarkers has been sparsely investigated in relation to cardiovascular events. We evaluated a novel biomarker of COL VI formation as a prognostic marker for cardiovascular events and mortality in patients with type 2 diabetes from the Canagliflozin Cardiovascular Assessment Study (CANVAS).

Methods

COL VI formation was assessed with the PRO-C6 enzyme-linked immunosorbent assay (ELISA), detecting a specific fragment of COL VI released upon deposition in the extracellular matrix. PRO-C6 levels were measured in baseline plasma samples from 3531 patients from CANVAS. Results from Cox proportional hazard regression models were reported as unadjusted or adjusted for the traditional risk factors age, sex, BMI, systolic and diastolic blood pressure, duration of diabetes, LDL cholesterol, HbA1c, eGFR, and albumin/creatinine ratio.

Results

In the unadjusted analysis, levels of PRO-C6 were significantly associated with heart failure (HF), cardiovascular death (CVD), a composite of HF and CVD, and all-cause mortality (Table, all P<0.0001). To assess the independent association of PRO-C6 with these outcomes, the analysis was adjusted for traditional risk factors. In the adjusted analysis, PRO-C6 was significantly associated with the listed outcomes (Table, all P≤0.0001).

Conclusion

In conclusion, this study reveals an independent association of the COL VI biomarker PRO-C6 with cardiovascular events and mortality in the CANVAS study.

Funding

  • Commercial Support –